Raman Pharma is a UK based MHRA and VMD Licensed Wholesaler supplying to the Human and Veterinary Market. We are a family run company ambitiously changing the face of the Pharmaceutical and Veterinary Market alike in order to serve the needs of our customers and their patients.
Our Philosophy and business are structured around the requirements of our customers and we are committed to giving them our upmost attention and care. We believe in delivering quality and value to our customers wherever they may be.
The Herbal Horse and Pet is a South African manufacturer of a very innovative range of supplements for horses, dogs and cats. Their philosophy of using a large number of different ingredients in small amounts mimics nature in that the healing effect of the ingredients is maximised while undesirable side-effects are minimised. These unique formulations, in conjunction with 21st century scientific research and techniques are what they call “cutting edge nature”.
They are manufactured in a GMP Compliant Factory and has a large following from riders and pet owners across the world. Please follow the link to the website – www.theherbalhorse.co.uk to see all the amazing blogs and the ability to purchase these products online. The Equine and Pet Range were introduced to the UK Market in September 2014 by Raman Pharma to give the UK a taste of the future in equine and companion animal nutritional supplements.
"Fantastic service, Really helpful & always able to source products that we need at very competitive prices. Would thoroughly recommend to any Veterinary Practice"
"Raman Pharma have been invaluable in sourcing drugs that are out of stock elsewhere. Delivery is rapid, costs are good and the customer service provided by Dhruv is excellent. I would definitely recommend this company and its services to others."
Department of Health and Social Care (DHSC) has issued a supply disruption notification for Berinert (Human C1 Esterase inhibitor) 500IU powder and solvent for injection as limited stock remains in the supply chain. Further information and management advice can be found in the alert. The DHSC Medicine Supply Team provide a monthly update on potential...
Further to our news story Temporary parallel export ban issued to ensure continued supply of medicines the Department of Health and Social Care (DHSC) and the Medicines and Healthcare products Regulatory Agency (MHRA) has announced that Colestyramine sachets and Fluticasone nasules are to be added to the list of medicines which must not be parallel exported...
Drug alert number: EL (19)A/40 Date issued: 5 December 2019 Accord Healthcare are recalling all unexpired stock of the products listed below from pharmacies and wholesalers as a precautionary measure due to possible contamination with an impurity Nnitrosodimethylamine (NDMA) which has genotoxic and carcinogenic potential. Product PL Number Ranitidine 150mg Film-Coated Tablets 20075/0063 Ranitidine 300mg...
The November 2019 edition of PSNC’s Community Pharmacy News (CPN) is now available. This month’s CPN features: Pharmacy Representation Review; Joint pharmacy manifesto; CPCS queries answered; and Suppliers’ Xmas opening. View our CPN magazine online via the flipbook reader below or download the PDF copy. Please note, the colour PDF can be printed out in...
The PSNC Committee met recently, with key discussions around progress with new services alongside concerns around funding and capacity pressures. PSNC’s November meeting was held on the 27th and 28th of the month, and other key agenda items included: Services developments for 2020/21; Changes to reimbursement; Medicine supply and shortages; Pharmacy consolidations; Contractor support and...
This PSNC Briefing provides a list of all the PSNC resources available to assist community pharmacy contractors with meeting the gateway and quality criteria of the Pharmacy Quality Scheme (PQS) 2019/20. PharmOutcomes services and assessments, which are relevant for the PQS, are also listed in this Briefing as PSNC has agreed to use their licence...
Develop your skills and confidence in engaging with people who have depression with the Centre for Pharmacy Postgraduate Education (CPPE)’s latest course. We spoke to Sneha Varia, CPPE East of England Regional Manager, to find out more. We are pleased to announce the launch of our new Depression Optimise programme. At least a third of the English...
Department of Health and Social Care (DHSC) has today (03/12/2019) set the FINAL price concession for November 2019. The new addition to the November 2019 price concession list is below: Drug Pack size Price Concession Irbesartan 300mg / Hydrochlorothiazide 12.5mg tablets 28 £11.44 DHSC previously granted the following price concessions for November 2019: Drug Pack...
The Department of Health and Social Care (DHSC) has via its Central Alerting System (CAS) published a letter advising that due to increasing flu levels in the community, GPs and other prescribers working in primary care in England may now prescribe antiviral medicines for the prophylaxis and treatment of flu at NHS expense. Prescribers may...
NHS Digital is seeking feedback from community pharmacy about the use of NHSmail shared mailboxes and their naming rules. PSNC – in its role as part of the Community Pharmacy IT Group (CP ITG) – has received feedback from community pharmacy NHSmail users that the shared mailbox email addresses naming could be improved. A message...
MHRA update on metformin medicines.
List of companies in the UK who have their licence to manufacture or wholesale medicines terminated and cancelled.
List of sites granted a manufacturer or wholesale dealer licence
Current listing of UK brokers authorised to broker human medicines, including company name, registration and address.
Guidance on how to get an e-cigarette on the market in the UK, including the notification scheme and reporting problems with e-cigarettes.
Public list of companies in the UK who have had their licence/registration to manufacture or wholesale medicines/ingredients revoked or suspended.
Expected time taken to process and grant a marketing authorisation or a variation to a marketing authorisation.
The number of applications pending, refused and granted for the early access to medicines scheme (EAMS).
Manufactured by Natus - GN Otometrics A/S: an exposed conductor may cause an electric shock to the user or patient.
Accord Healthcare are recalling all unexpired stock of the below products from pharmacies and retail stores as a precautionary measure.
EAMS scientific opinion given to Aventis Pharma in the treatment of adult patients with relapsed and refractory multiple myeloma.
Manufactured by Terumo BCT – inadequately broken anticoagulant ‘frangible’ may lead to clotting and inadequate therapy during apheresis procedures.
Sets out medicines that cannot be parallel exported from the UK because they are needed for UK patients.
List of field safety notices (FSNs) from medical device manufacturers from 25 October to 29 November 2019.
Pharmaswiss Česka republika s.r.o. (an affiliate of Bausch & Lomb UK Limited) is recalling all unexpired batches of Emerede Adrenaline Autoinjectors after identifying an error than can cause some pens to fail to activate.
How to join the phase I accreditation scheme.
Information on Medicines and Healthcare products Regulatory Agency spending over £25,000.
Pharmaswiss Česka republika s.r.o. (an affiliate of Bausch & Lomb UK Limited) is recalling all unexpired batches of Emerede Adrenaline Autoinjectors after identifying an error than can cause some pens to fail to activate.
Manufactured by Becton Dickinson – if a software security vulnerability is exploited, an attacker with malicious intention could remotely install unauthorised firmware.
M&A Pharmachem Limited is recalling all unexpired batches as a precautionary measure, because a small number of pots from some batches have been found to contain discoloured tablets due to fungal contamination.
The European Medicines Agency have issued advice for users of live PRRS vaccines.
Details of the improvement notice served to Alex the Vet, Uckfield, East Sussex. Published in December 2019.
How to legally run a business that deals with the wholesale of animal medicines (veterinary medicinal products) and the WDA Register.
Freedom of Information (FOI) requests received by the Veterinary Medicines Directorate (VMD) 1 January and 30 June 2019
Details of seizure notice served to SF Equine Vets Ltd, Maldon, Essex. Published in November 2019.
Validation during the Christmas period 2019 for an application for an MA, ManA, WDA, Batch Release and Export Certificate.
Details of seizure notice issued to NPD Ventures Ltd (T/A World of Pets) at the National Pet Show, NEC Birmingham Published November 2019
Guidance on applying to vary a veterinary Marketing Authorisation (MA).
The VMD telephone lines are now up and running.
Reporting against VMD published standards up to 31 October 2019.
Details of seizure notice issued to Pawfection Pets, Abertillery, Wales.
Reported problems with the supply of an animal medicine and the date when the issue is expected to be resolved.
Start using the new @vmd.gov.uk email address now.
Guidance on applying for an authorisation to manufacture veterinary medicines.
Marketing Authorisations Information Service (MAVIS) Hub edition 112
This report (UK VARSS) provides the details of UK veterinary antibiotic resistance and sales surveillance.
This is the hub for all the Veterinary Medicines Directorate's communications on Brexit which includes guidance on how you can prepare.
This report (UK VARSS) provides the details of UK veterinary antibiotic resistance and sales surveillance.
New VARSS report confirms that sales of veterinary antibiotics have halved over the past four years.
This report (UK VARSS) provides the details of UK veterinary antibiotic resistance and sales surveillance.
The French drugmaker is spending around $2.5 billion on the deal
The drug demonstrates “remarkable efficacy”, says AZ’ José Baselga
Policymakers must identify fragmented systems and promote better data sharing, study authours say
Janssen's JNJ-4528 and BMS/bluebird bio's liso-cel show 100% response rates
Genetic regulation is set to become a fifth primary focus for the Japanese drugmaker, on top of its already existing business lines.
The online retail giant's honed data abilities will help Novartis produce more personalised therapies.
The treatment could offer a new option for patients unable to reach viral supression
This year's competition welcomed a fantastic spread of companies as well as a higher number of entrants
Flying the flag for clinical research for over 20 years, this competition continues to grow and develop year after year.
If approved, the drug will be the only non-binder treatment for the control of serum phosphorus in patients with CKD on dialysis.
The fish oil-derived therapy is already approved in the US for patients with severe hypertriglyceridaemia.
The system gives users “greater flexibility” to customise the company's established CRM.
The drug only managed to reach an efficacy of 7.4% in 'peak season' and 9.8% in the whole season, falling short of the expected 20%.
Galapagos and Gilead initially entered into a global collaboration for the development and commercialisation of the drug in inflammatory indications in 2015.
The drug was cleared for small cell lung cancer back in March.
Unit 2 Fleet Business Park, Sandy Lane, Church Crookham, Fleet, Hampshire, GU52 8BF
Pharmaceutical and Veterinary Licensed Distributor. WDA (H) 43703 & WDA (V) 43703.
- +44 (0)1252 260 460.
- +44 (0)1276 469 290
Monday to Friday - 09:30 – 18:30
Saturday & Sunday - Closed, Online Ordering Available
